Suppr超能文献

恶性胸膜疾病

Malignant pleural diseases.

作者信息

Rodriguez-Panadero F

出版信息

Monaldi Arch Chest Dis. 2000 Feb;55(1):17-9.

Abstract

The incidence of malignant pleural effusions has been increasing over the last few decades (mainly due to the absolute increase in several types of cancers, especially those of lung and breast origin) and they account for up to 50% of the exudates in many clinical series. Although pleural malignancies are thought to present most frequently with a pleural effusion, several autopsy series, including the current one, found a pleural effusion present in little more than half of the cases of malignant pleural involvement (55% in this series). Thus, many pleural malignancies without effusion might pass unnoticed in clinical practice, especially in metastatic disease. Primary malignancies of the pleura (mesotheliomas) are associated with asbestos exposure in about two-thirds of cases, and they frequently present with chest pain, sometimes associated with a pleural effusion. Benign pleural plaques can coexist with malignant mesothelioma, and this association should be suspected when long-standing plaques change in shape or size over the years, and especially if chest pain develops in a previously asymptomatic patient. Metastatic pleural involvement is much more frequent than mesotheliomas, and its most frequent mechanism is the vascular spreading of tumour cells from distant organs to the lungs, and on to the visceral and parietal pleura. The visceral pleura was involved in up to 87% of the current metastatic cases, whereas the parietal zone in only 47% of the autopsy series. The diagnostic work-up lies in cytology, whose average yield is approximately 50%, and a biopsy technique (either by blind needle biopsy or thoracoscopy) is recommended when the effusion persists, for > 2 weeks, and the first cytology has been negative. Thoracoscopy has the additional advantage of allowing pleurodesis with talc poudrage if clear tumour lesions are found in the pleura. In cases of malignant effusion which are not sensitive to chemotherapy, pleurodesis is the treatment of choice for palliation of symptoms, and talc is the most effective agent. It can be used either in suspension ("slurry") or in dry aerosolized form ("talc poudrage"), but it seems that this last technique achieves the best effects. However, it requires thoracoscopy for a proper application, and this is its main drawback when that technique is not readily available.

摘要

在过去几十年中,恶性胸腔积液的发病率一直在上升(主要是由于几种癌症的绝对数量增加,特别是肺癌和乳腺癌),在许多临床病例系列中,它们占渗出液的比例高达50%。尽管胸膜恶性肿瘤被认为最常表现为胸腔积液,但包括本次研究在内的多个尸检系列发现,在胸膜恶性受累病例中,只有略多于一半的病例存在胸腔积液(本系列中为55%)。因此,许多没有胸腔积液的胸膜恶性肿瘤在临床实践中可能未被注意到,尤其是在转移性疾病中。胸膜原发性恶性肿瘤(间皮瘤)在约三分之二的病例中与石棉暴露有关,并经常表现为胸痛,有时伴有胸腔积液。良性胸膜斑可与恶性间皮瘤共存,当长期存在的胸膜斑多年来形状或大小发生变化,特别是如果先前无症状的患者出现胸痛时,应怀疑这种关联。转移性胸膜受累比间皮瘤更为常见,其最常见的机制是肿瘤细胞从远处器官经血管扩散至肺部,进而累及脏层和壁层胸膜。在本次转移性病例中,高达87%的病例累及脏层胸膜,而在尸检系列中,壁层胸膜受累的病例仅占47%。诊断检查依赖于细胞学检查,其平均阳性率约为50%,当胸腔积液持续超过2周且首次细胞学检查为阴性时,建议采用活检技术(盲针活检或胸腔镜检查)。如果在胸膜中发现明确的肿瘤病变,胸腔镜检查还有额外的优势,即可以通过滑石粉喷洒进行胸膜固定术。对于对化疗不敏感的恶性胸腔积液病例,胸膜固定术是缓解症状的首选治疗方法,滑石粉是最有效的药物。它可以以悬浮液(“浆液”)或干粉雾化形式(“滑石粉喷洒”)使用,但似乎最后一种技术效果最佳。然而,它需要通过胸腔镜进行适当应用,当该技术不易获得时,这是其主要缺点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验